7 June 2022
What's new in immunotherapies 2022
Organised by:
SCI, London, UK
Register your interest
Registration Closed
This event is no longer available for registration.
Share this event
Synopsis
Immunotherapy is a hot-topic field of research that has generated significant scientific interest and fuelled industrial innovation.
It has been demonstrated that small, drug-like molecules can be highly effective modulators of immune response pathways and that their molecular properties can be fine-tuned to enable excellent cell permeability and bioavailability. This makes them ideal for use in the treatment of chronic conditions such as autoimmune and inflammation-related diseases. Excitingly, this approach also offers the possibility to treat cancer by harnessing the body’s own immune system to fight tumours.
This meeting will offer a broad introduction to those new to the topic and showcase recent innovations by academic and industrial scientists in this exciting and rapidly expanding field.
Call for posters
An abstract of maximum one A4 page or 300 words indicating title and authors should be sent to conferences@soci.org by Friday 29 April with the subject line “What's New in Immunotherapies - poster abstract submission". Please use the template attached here.
Attendees
The event is targeted at research students, researchers, academic and industrial scientists engaged in all aspects of research into small molecule immunotherapy, and those interested in broadening their knowledge in this growing field.
This event is being held back to back with "Targeting protein degradation 3 – from discovery to the clinic".
7 June 2021
- 09:00
- Registration and Refreshments
- 09:50
- Welcome and introduction
- 10:00
- In vitro assays for immunotherapy drug discovery programs; overview and emerging areas
Dr Justyna Rzepecka, Concept Life Sciences - 10:40
- TBC
Prof. Edward Tate; Imperial College Myricx Pharma Ltd and Crick Institute - 11:20
- Optimisation of Mer/Axl kinase inhibitors for immuno-oncology
Dr William McCoull, AZ - 12:00
- Lunch and poster session
- 13:30
- The discovery of BD2 selective BET inhibitors
Dr Emmanuel Demont, GSK - 14:10
- First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumour growth inhibition
Andrew Leishman, Grey Wolf therapeutics - 14:50
- Refreshments
- 15:20
- Discovery and Development of Novel Small Molecule Inhibitors of IL-17
Dr Anne Foley, UCB - 16:00
- Enabling Natural Killer Cell Immunotherapy of Cancer with Small Molecules
Prof. Matt Fuchter Imperial College and NK:IO Ltd - 16:40
- Panel Discussion
- 17:30
- Wine Reception
Fees
| Before early bird - ends 26 April 2022 SCI Member - £80 Non-member - £120 Student member - £35 |
| After early bird SCI Member - £130 Non-member - £170 Student member - £50 |
There is a 10 percent reduction on the registration fee if you register for the Targeting protein degradation 3 – from discovery to the clinic event in addition to this meeting for SCI members and non-members.
Once you have registered for this event, please email conferences@soci.org for a voucher code.
All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email conferences@soci.org.
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
CPD Information
SCI Members attending this meeting are able to claim CPD points.
Sponsors
Sponsorship
For further information and prices, please email conferences@soci.org
Organising Committee
- Tilly Bingham, SCI/ Concept Life Sciences
- Nicola Chessum, SCI
- Jayshree Mistry, SCI/ Modgraph Consultants
Contact
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
